The program is available below, along with videos of presentations that have been released by the speakers.
|
Also available to download is a PDF program that includes speaker biographies and poster abstracts. You may also view speaker biographies and poster abstracts on this website. |
PROGRAM
Overview
Metabesity is the constellation of chronic diseases and complications of senescence, all which share metabolic, inflammatory, and other drivers.
To the extent that these conditions have common pathogenetic roots, they can be collectively targeted. The intent of naming this target is to recruit diverse thinking and doing across the landscape of biomedical research, solution development, public policy, commercialization, healthcare integration, and education. This program is designed to reflect, in microcosm, these constituencies and their contributions, considerations, and challenges.
Overview
Metabesity is the constellation of chronic diseases and complications of senescence, all which share metabolic, inflammatory, and other drivers.
To the extent that these conditions have common pathogenetic roots, they can be collectively targeted. The intent of naming this target is to recruit diverse thinking and doing across the landscape of biomedical research, solution development, public policy, commercialization, healthcare integration, and education. This program is designed to reflect, in microcosm, these constituencies and their contributions, considerations, and challenges.
|
DAY 1 | TUESDAY, 15 OCTOBER 2019 | 8:30 AM - 5:30 PM
THE SCIENCE AND THE SCIENTIFIC INFRASTRUCTURE FOR TARGETING METABESITY 7:30 AM – 8:30 AM | REGISTRATION AND CONTINENTAL BREAKFAST 8:30 AM – 9:45 AM | SESSION 1
INTRODUCTION AND KEYNOTES The introduction by the Co-chairs sets the stage by articulating the distinctive theme of the conference, on the emerging Science of Metabesity (the focus of Day 1) and its Translation into material, accessible gains in public health (the focus of Day 2). The Directors of NIA/NIH and of CDER/FDA will anticipate these themes, the former on the basic and translational science conducted and funded by NIA, and the latter on considerations for the important issue of regulatory pathways for prevention and extension of healthy lifespan claims. 8:30 AM – 8:40 AM | Introduction to Metabesity Alexander Fleming, MD, Founder and Executive Chairman of Kinexum, USA and Lawrence Steinman, MD, Professor at Stanford University, USA (Co-chairs) 8:40 AM – 9:05 AM | Progress and plans at the National Institute on Aging Richard Hodes, MD, Director of the National Institute on Aging (NIH), USA 9:05 AM – 9:30 AM | Challenges in Drug Development for New Preventive Indications Janet Woodcock, MD, Director of FDA Center for Drug Evaluation and Research, USA 9:30 AM – 9:45 AM | Q&A / Discussion 9:45 AM – 11:15 AM | SESSION 2
GEROSCIENCE A panel of leading researchers in geroscience will discuss the latest science that encourage intervention against Metabesity to reduce age-related complications. Moderator: Richard Hodes, MD, Director of the National Institute on Aging (NIH), USA Targeting the body’s natural defenses against aging and age-related diseases David Sinclair, PhD, Co-Director of the Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, USA New paths from basic research toward clinical trials in geroscience Matt Kaeberlein, PhD, Director of the Healthy Aging and Longevity Research Institute, University of Washington, USA From longevity signatures to longevity interventions Vadim Gladyshev, PhD, Professor of Medicine and Director, Center for Redox Medicine, Brigham and Women’s Hospital, Harvard Medical School, USA Video Not Released Interventions at the crossroad of aging and metabolism Brian Kennedy, PhD, Director of the Centre for Healthy Ageing at the National University Health System, Singapore Q&A / Discussion - Video Not Released 11:15 AM – 11:35 AM | MORNING COFFEE BREAK 11:35 AM – 1:05 PM | SESSION 3
CANCER, NEURODEGENERATIVE DISEASES AND CARDIOVASCULAR DISEASES A distinguished panel of researchers and clinicians in geroscience, cancer, neurodegenerative diseases and other chronic diseases of aging (other than diabetes and metabolic diseases, which is the subject of Session 4 below) will discuss the scientific basis for addressing Metabesity and clinical approaches that can be applied. Moderator: Lawrence Steinman, MD, Professor of Neurology and Neurological Sciences, Pediatrics and Genetics, Stanford, USA - Co-chair Studying aging in humans Leonard Guarente, PhD, Director of the Paul F. Glenn Center for the Biology of Aging Research at MIT; Co-founder and Chief Scientist of Elysium Health, USA Video Not Released Mitochondria and cancer: Potential therapeutic opportunities Brian Leyland-Jones, MB, BS, PhD, FRACP, FRCPC, VP, Chief Medical Officer and Scientific Advisory Board Member for the National Foundation for Cancer Research (NFCR), USA Video Not Released Weight loss for cancer prevention and control Jennifer Ligibel, MD, Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living, Dana-Farber Cancer Institute, USA
Epigenetic resetting of cellular age mediated by nuclear reprogramming: A new paradigm in overcoming aging and aging-associated diseases Vittorio Sebastiano, PhD, Assistant Professor of Stanford University and Co-Founder of Turn Biotechnologies, USA Q&A / Discussion - Video Not Released 1:05 PM – 2:00 PM | LUNCH AND POSTER PRESENTATIONS 2:00 PM – 3:30 PM | SESSION 4
DIABETES, OBESITY AND OTHER METABOLIC DISEASES A distinguished panel of diabetologists/endocrinologists will debate the science supporting targeting Metabesity through various modalities, including pharmacology, devices, nutrition, and others. Moderator: Jay Skyler, MD, MACP, Professor of Medicine, Pediatrics and Psychology at the University of Miami, USA Type 2 diabetes is a lifelong disease John Buse, MD, PhD, Professor of Medicine, Director of Diabetes Care Center of University of North Carolina, USA T2DM: A cardio metabolic disease linked by insulin resistance Ralph DeFronzo, MD, Professor of Medicine, University of Texas Health Science Center, San Antonio, USA Video Not Released Nonalcoholic steatohepatitis with liver fibrosis (NASH) in patients with DM type II and hyperlipidemia: Is the horse out of the barn? Brian Harvey, MD, PhD, EVP of Global Liver Institute, USA Insights on the origins and effects of metabolic damage in type 2 diabetes Professor Philip Home, MA DPhil DM FRCP, Professor of Diabetes Medicine, University of Newcastle, UK Q&A / Discussion - Video Not Released 3:30 PM – 3:45 PM | AFTERNOON BREAK 3:45 PM – 5:15 PM | SESSION 5
NUTRITION, LIFESTYLE AND SOCIAL APPROACHES To prevent or delay chronic diseases of aging, it will take more than drugs: nutrition, exercise, medical devices that alter behaviors, stress relief, socialization, and other modalities will be part of the solution. Moderator: Lucy Rose, Founder and President of The Cost of Loneliness Project, USA; Former Director of the Division of Drug Advertising and Marketing, CDER, FDA, USA Nutrigerontology: Using insights into the aging process to provide better nutrition guidelines to address metabolic diseases and to live longer, healthier lives Kris Verburgh, MD, Researcher at the Free University Brussels, Belgium, and Venture Partner of Longevity Vision Fund
Proven Ways to Prolong Quality Lives and Decrease the Cost of Healthcare Kenneth Cooper, MD, MPH, Founder of The Cooper Institute, USA
The cost of loneliness Lucy Rose, Founder and President of The Cost of Loneliness Project, USA; Former Director of the Division of Drug Advertising and Marketing, CDER, FDA, USA Video Not Released Q&A / Discussion 5:15 PM – 5:30 PM | SUMMARY OF DAY 1 AND LOOK AHEAD TO DAY 2 5:30 PM – 7:30 PM | COCKTAIL RECEPTION |
DAY 2 | WEDNESDAY, 16 OCTOBER 2019 | 8:30 AM - 5:45 PM
TRANSLATION OF METABESITY SCIENCE TO PEOPLE 7:30 AM – 8:30 AM | REGISTRATION AND CONTINENTAL BREAKFAST 8:30 AM – 9:40 AM | SESSION 6
KEYNOTES The Directors of NHLBI/NIH and of CFSAN/FDA will recapitulate the Science and Translation theme of the conference, in the context of the important progress that has been made in recent decades in prevention, not just treatment, of cardiac and related events, and regulatory considerations for the increasing understanding of the role of nutrition in health and medicine. 8:30 AM – 8:35 AM | Day 2 Introduction Alexander Fleming, MD, Founder and Executive Chairman of Kinexum, USA and Lawrence Steinman, MD, Professor at Stanford University, USA (Co-chairs)
8:35 AM – 9:00 AM | Translating discovery science for precision prevention Gary Gibbons, MD, Director of the National Heart, Lung, and Blood Institute (NHLBI) at NIH, USA 9:00 AM – 9:25 AM | FDA’s role in nutrition and chronic disease prevention Susan Mayne, PhD, Director of FDA Center for Food Safety and Applied Nutrition, USA
9:25 AM – 9:40 AM | Q&A / Discussion 9:40 AM – 11:00 AM | SESSION 7
CLINICAL DEVELOPMENT ISSUES – CHALLENGES AND OPPORTUNITIES Clinical development is another major challenge for targeting Metabesity. Demonstrating safety and efficacy for prevention and delay could require vast trials over decades based on the classical approach to clinical development. Some large trials are being performed, e.g. for cardiovascular outcomes and NASH, and aging endpoints might be tractable under designs like the Targeting Aging with Metformin (TAME) trial. In other cases, pragmatic trials and Real World Evidence may be able to contribute necessary data, while biomarker and surrogate endpoint validation, e.g. using tools like AI, may keep clinical trials manageable. Moderator: Jay Skyler, MD, MACP, Professor of Medicine, Pediatrics and Psychology at the University of Miami, USA How to live long to a ripe young age Nir Barzilai, MD, Director of Institute for Aging Research, Albert Einstein College of Medicine, USA Considerations of cohort heterogeneity in chronic disease research William Cefalu, MD, Director of the Division of Diabetes, Endocrinology & Metabolic Diseases, NIDDK/NIH, USA Video Not Released Connecting preclinical discovery and clinical development through AI Alex Zhavoronkov, PhD, CEO of InSilico Medicine, USA Q&A / Discussion - Video Not Released 11:00 AM – 11:15 AM | MORNING COFFEE BREAK 11:15 AM – 11:35 AM | SESSION 8
PAYERS AND PROVIDERS Closely related to regulatory labels and clinical evidence is the question of how payers and providers are incentivized with respect to Metabesity approaches. A traditional insurer may be ambivalent about paying for preventative therapies that may not ‘pay off’ in the form of delayed or avoided chronic illnesses decades later, when a different payer may be involved. A traditional insurer, a managed care provider, a new business model for saving healthcare costs and a single payer government system may have different perspectives on how to achieve extended healthspan. Fireside Chat between Ed Saltzman, Executive Chairman of Cello Health BioConsulting, and Ryan Walsh, Vice President for Client Services for Real Endpoints, USA 11:35 AM – 1:05 PM | SESSION 9
INDUSTRY: ESTABLISHED COMPANIES There is a growing ecosystem of some more established companies, as well as emerging companies, that are targeting Metabesity or watching those that are. Session 9 will feature the view from Big Pharma, Big Nutrition, Digital Health and others. Moderator: Joe Cook, Jr. The overlap of metabolic diseases and early aging... A working hypothesis for changing how we address this space Joe Cook, Jr., Executive Chairman and President of NuSirt Biopharma; former Chairman and CEO of Amylin, USA Novel therapies that are increasing our understanding of disease and leading to changes in drug development Stephen Gough, MD, FRCP, SVP Global Chief Medical Officer of Novo Nordisk, Denmark Data and advanced analytics to accelerate the translation of science that matters to patients Zsolt Bosnyak, MD, PhD, Global Medical Head of the Insulins Franchise and Diabetes Solution, Sanofi, France
Digital health as a platform for improving cardiometabolic health Bimal Shah, MD, CMO of Livongo Health, USA
Aging: An opportunity to nurture vitality Pietro Antonio Tataranni, MD, Deputy Chief Scientific Officer and Senior Vice President of Life Sciences at PepsiCo R&D, USA Q&A / Discussion 1:05 PM – 1:50 PM | LUNCH AND POSTER PRESENTATIONS 1:50 PM – 3:20 PM | SESSION 10
INDUSTRY: EMERGING COMPANIES Joining larger companies in the Metabesity ecosystem are emerging companies that are targeting multiple chronic diseases and longevity based on a variety of approaches. Leaders of emerging companies will discuss major topics, including drug-facing versus/and consumer-facing business models, the appropriate standards and role of clinical, biomarker and other evidence in regulatory and clinical development and commercialization, and possible contours of the emerging longevity industry. Moderator: Ed Saltzman, Executive Chairman, Cello Health BioConsulting, USA Targeting the biology of aging as a new way to prevent and treat aging-related diseases Joan Mannick, MD, Co-Founder and CMO of resTORbio, USA Video Not Released Novel approach to developing therapies for diseases of aging Sree Kant, Head of Business Development for Life Biosciences, USA Video Not Released NuSirt: “Metabesic” therapeutic targets via novel Sirtuin/AMPK co-activation Michael Zemel, PhD, Founder and Chief Scientific Officer of NuSirt Biopharma, USA Apelin Peptide: An unexpected 20 year journey of the evolutionary longevity agent John Chan, PhD, CEO of the Apelin Project, USA Video Not Released Addressing the metabolic deficit in Alzheimer’s disease Charles Stacey, MD, President and CEO of Cerecin, USA Q&A / Discussion - Video Not Released 3:20 PM – 4:05 PM | SESSION 11
A VIEW FROM THE CAPITAL MARKETS Funders targeting longevity will share views on investment approaches and a range of business model and strategy topics, which could include drug-facing vs.consumer-facing models, targeting specific diseases vs. mass market targets, organizational structures such as incubator or AI tool platform and subsidiaries targeting specific diseases or hallmarks of aging, how exits might emerge, and what investors want to see from scientists, policy makers, regulators and industry. Moderator: Dennis Purcell, Founder and Senior Advisor of Aisling Capital, USA Longevity industry investing requires more advanced and sophisticated analytical methods and de-risking techniques Kate Batz, Managing Partner of Longevity.Capital, USA Laura Deming, Founder and Partner of The Longevity Fund, USA Video Not Released Q&A / Discussion - Video Not Released 4:05 PM – 5:00 PM | SESSION 12
FOUNDATIONS, PATIENTS AND GOVERNMENT What can foundations and other not-for-profit entities, patient groups, government, and society at large do, and what are they interested in doing, to promote the delay and prevention of chronic diseases of aging and the extension of health span? What should the role and prioritization of healthy longevity be in the context of other big challenges and opportunities in coming decades? Moderator: Jamie Metzl, Author of Hacking Darwin: Genetic Revolution and the Future of Humanity, USA Leveraging the membership in professional societies to expand the metabesity movement Karen Tracy, Vice President, Strategic Alliances and Integrated Communications for The Gerontological Society of America (GSA), USA What to learn from the UK’s All Party Parliamentary Group on Longevity and an industrial strategy on healthy ageing Eric Kihlstrom, Strategic Director of Aging Analytics Agency and Secretariat for the UK All-Party Parliamentary Group (APPG) on Longevity, UK Video Not Released Q&A / Discussion 5:00 PM – 5:30 PM | SESSION 13 SUMMATION AND A LOOK AHEAD Moderated panel discussion |